Evidence map›Paper›PMID 34832863›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses.

Dinoop Ravindran Menon, Yang Li, Takeshi Yamauchi, Douglas Grant Osborne, Prasanna Kumar Vaddi, Michael F Wempe, Zili Zhai, Mayumi Fujita

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. miR395e fromGenes · 2025
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Dinoop Ravindran MenonDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-6335-9227
Yang LiDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0001-7242-4687
Takeshi YamauchiDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Douglas Grant OsborneDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Prasanna Kumar VaddiDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Michael F WempeDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Zili ZhaiDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Mayumi FujitaDepartment of Dermatology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.ORCID 0000-0002-1498-1925
University of Colorado Anschutz Medical Campus · USVA Eastern Colorado Health Care System · US

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
Transgenic and Gene Targeting CoreP30AR057212 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI HOGAN, CHRISTOPHER J · 2009 to 2018
$6.2M
The role of IL-37 in human regulatory T cells, SupplementR01AI156534 · NIAID · UNIVERSITY OF COLORADO DENVER · PI FUJITA, MAYUMI · 2021 to 2025
$3.0M
Modulation of Inflammasome-mediated cytokine activation by EGCG in human melanomaR01CA197919 · NCI · UNIVERSITY OF COLORADO DENVER · PI FUJITA, MAYUMI · 2016 to 2020
$1.9M
Autoinflammation in Human MelanomaI01BX001228 · VA · VA EASTERN COLORADO HEALTH CARE SYSTEM · PI FUJITA, MAYUMI · 2012 to 2022
–
BLRD VA I01 BX001228Cancer League Colorado NANCI NIH HHS CA197919NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA197919NIAID NIH HHS R01 AI156534NIAMS NIH HHS P30 AR057212United States Department of Veterans Affairs 5I01BX001228
6 · The paper itself

Abstract

Over the last decade, therapies targeting immune checkpoints, such as programmed death-1 (PD-1), have revolutionized the field of cancer immunotherapy. However, low response rates and immune-related adverse events remain a major concern. Here, we report that epigallocatechin gallate (EGCG), the most abundant catechin in green tea, inhibits melanoma growth by modulating an immune response against tumors. In vitro experiments revealed that EGCG treatment inhibited interferon-gamma (IFN-γ)-induced PD-L1 and PD-L2 expression and JAK-STAT signaling. We confirmed that this effect was driven by inhibiting

Indexed as

EGCGIFN-γ signalingJAK-STAT signalingmelanoma immunotherapyPD-L1PD-L2

Identifiers

PMID34832863
PMCPMC8618268
OpenAlexW3209758450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.